Monday, June 2, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Merck, Daiichi Pull US Application for ‘guided Missile’ Therapy for Lung Cancer

May 29, 2025
in Health News
Share on FacebookShare on Twitter


(Reuters) -Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a late-stage study, the companies said on Thursday.

The treatment, patritumab deruxtecan, belongs to a class of targeted cancer therapies called antibody drug conjugates (ADC) that work like “guided missiles” by killing tumor cells while leaving healthy ones unharmed.

Patritumab deruxtecan is one of the three lucrative “guided missile” therapies that Merck has been working on with Daiichi in an effort to offset the loss of exclusivity for its top-selling cancer drug Keytruda.

The therapy failed the secondary goal of the study as it did not improve overall survival, defined as the length of time patients lived from the start of treatment. However, it met the main goal of helping delay progression of the cancer last year.

Patritumab deruxtecan and two other ADCs – ifinatamab deruxtecan and raludotatug deruxtecan – were part of Merck’s up to $22 billion joint development and commercialization deal with Daiichi signed in 2023.

The companies said on Thursday they were conducting further analyses to better identify lung cancer patients that may benefit from patritumab deruxtecan.

The U.S. Food and Drug Administration had declined to approve the therapy last year due to issues with a third-party manufacturing facility.

The companies had sought approval for the drug to treat non-small cell lung cancer in patients who have failed two or more prior lines of therapy and who had a mutation in the EGFR gene that leads to abnormal cell growth.

EGFR-positive lung cancer represents about 10% to 15% of lung cancers in the United States, according to the American Lung Association.

Johnson & Johnson’s Rybrevant and AstraZeneca’s Tagrisso are currently approved in the U.S. for EGFR-mutated non-small cell lung cancer.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas and Devika Syamnath)



Source link : https://www.medscape.com/s/viewarticle/merck-daiichi-pull-us-application-guided-missile-therapy-2025a1000e5g?src=rss

Author :

Publish date : 2025-05-29 11:14:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Amazing images reveal new details in the sun’s atmosphere

Next Post

Recommendation May Increase Prenatal Partners’ Vaccinations

Related Posts

Health News

Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

June 2, 2025
Health News

Neurodevelopmental and Psychiatric Disorders in Duchenne Muscular Dystrophy

June 2, 2025
Health News

Starting a New Hospital Job? Here’s How to Adapt

June 2, 2025
Health News

FDA Authorizes AI Platform for Breast Cancer Risk Prediction

June 2, 2025
Health News

Best quantum ‘transistor’ yet could lead to more accurate computers

June 2, 2025
Health News

Methotrexate for Osteoarthritis: Dead End After All?

June 2, 2025
Load More

Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

June 2, 2025

Neurodevelopmental and Psychiatric Disorders in Duchenne Muscular Dystrophy

June 2, 2025

Starting a New Hospital Job? Here’s How to Adapt

June 2, 2025

FDA Authorizes AI Platform for Breast Cancer Risk Prediction

June 2, 2025

Best quantum ‘transistor’ yet could lead to more accurate computers

June 2, 2025

Methotrexate for Osteoarthritis: Dead End After All?

June 2, 2025

UK Pharmacies Struggle with Severe Creon Shortage

June 2, 2025

From ’10/10′ Pain to ’10/10′ Healthcare

June 2, 2025
Load More

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version